Please login to the form below

Not currently logged in
Email:
Password:

S-A takeover approach rejected

Sanofi-aventis' suspected takeover approach for Genzyme has been rejected, according to two sources

Sanofi-aventis' (S-A) suspected takeover approach for Genzyme has been rejected, according to two sources.

Analysts have speculated that Genzyme, one of the world's leading biotechnology companies, could command at least $22bn, or $80 a share – a 48 per cent profit over Genzyme's closing price the day before S-A made its approach. It is thought that investors will insist on at least $20bn in a sale.

Genzyme could accrue an annual revenue of $6.6bn by 2013 if it resolves manufacturing defects that resulted in the figure dropping to $4.5bn in 2009.

GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) have also been rumoured to be bidding for Genzyme.

S-A and Genzyme have refused to comment on the claims.

27th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics